↑ 疾患リストへ ← 戻る

 179. ウィリアムズ症候群 [臨床試験数:4,薬物数:12(DrugBank:7),標的遺伝子数:7,標的パスウェイ数:8] 

Searched query = "Williams syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-006059-37-ES27/05/200919 March 2012ENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMSENSAYO CLÍNICO PILOTO, ALEATORIZADO, CONTROLADO, PARALELO, DOBLE-CIEGO, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE LOSARTÁN EN LA REDUCCIÓN DEL ESTRÉS OXIDATIVO Y LA DISMINUCIÓN DE LA TENSIÓN ARTERIAL (TA) EN PACIENTES CON SÍNDROME DE WILLIAMS (SW) Y DOS O MÁS COPIAS DEL GEN NCF1. - LOSARTANWILLIAMSPacientes con síndrome de Williams con evidencia molecular de microdeleción en 7q11.2. Edad: Niños de más de 5 años y adultos Sexo: ambos sexos estarán representados lo más paritariemente posible Variante molecular de la deleción que confirme la presencia de 2 o más copias del gen NCF1.
MedDRA version: 9.1 Level: LLT Classification code 10049644 Term: Williams syndrome
Trade Name: COZAAR 50 mg comprimidos recubierto con pelicula
Pharmaceutical Form: Oral solution
INN or Proposed INN: LOSARTAN POTASICO
Other descriptive name: LOSARTAN POTASSIUM
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Oral solution
Route of administration of the placebo: Oral use
Programa de Medicina Molecular y Genética, Hospital Vall d´HebronAuthorisedFemale: yes
Male: yes
60Spain
2EUCTR2006-005745-11-FR03/04/200819 March 2012Efficacité du minoxidil chez les enfants atteints du syndrome de Williams et Beuren : un essai clinique randomiséEfficacité du minoxidil chez les enfants atteints du syndrome de Williams et Beuren : un essai clinique randomiséWilliams syndrome
MedDRA version: 9.1 Level: LLT Classification code 10049644 Term: Williams syndrome
Trade Name: LONOTEN
Pharmaceutical Form: Tablet
INN or Proposed INN: MINOXIDIL
CAS Number: 38304915
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Hospices Civils de LyonAuthorisedFemale: yes
Male: yes
France
3NCT00768820May 200126 August 2019The Psychiatric and Cognitive Phenotypes in Velocardiofacial SyndromeThe Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (VCFS), Williams Syndrome (WS)and Fragile X Syndrome Characterization, Treatment and Examining the Connection to Developmental and Molecular FactorsVelocardiofacial Syndrome;Williams Syndrome;Fragile X SyndromeDrug: methylphenidate, fluoxetin, risperidoneThe Chaim Sheba Medical CenterRecruitingN/AN/AAll400Phase 4Israel
4NCT00013962September 199819 February 2015Vitamin D Metabolism and the Williams SyndromeVitamin D Metabolism and the Williams SyndromeWilliams SyndromeDrug: Vitamin DNational Center for Research Resources (NCRR)Not recruiting18 Years50 YearsBothN/AUnited States